Category: Latest News
-
AI Video Compression Platform Launch Positions Robo.ai for Physical AI Infrastructure Push
Robo.ai launched a new (AIIO) visual data infrastructure platform through its Neurovia AI subsidiary, targeting growing demand for AI-native compression and edge computing technologies. Key Investor Takeaways Why (NASDAQ:AIIO) Stock Is in Focus Robo.ai announced the official launch of NeuroStream™, a new technology platform designed to support visual data processing for Physical AI applications. According…
-
Rare Earth Acquisition Push Expands Mobix Labs Into Strategic Defense Supply Chains (MOBX)
Mobix Labs signed a non-binding agreement to acquire a U.S. rare earth and critical minerals platform, potentially expanding the company deeper into defense, aerospace, and AI infrastructure supply chains. Key Investor Takeaways Why Mobix Stock Is in Focus Mobix Labs announced it signed a non-binding letter of intent to acquire Special Project Delivery LLC (SPD),…
-
Multi-Year Singapore Security Contracts Expand Revenue Visibility for Concorde International (YOOV)
Concorde International secured more than $10 million in multi-year contracts tied to integrated security deployments across Singapore, strengthening the company’s position in AI-enabled security services. Key Investor Takeaways Why Concorde International Stock Is in Focus Concorde International announced it secured multi-year contracts worth more than $10 million for integrated security services across industrial zones, business…
-
Latin America Gaming Expansion Becomes New Growth Focus for Snail Games (SNAL)
Snail Games is increasing its presence in Latin America as the company looks to expand publishing partnerships and capitalize on growing engagement in one of the world’s fastest-growing gaming markets. Key Investor Takeaways Why Snail Stock Is in Focus Snail Games announced that it attended Gamescom LATAM as part of its effort to expand operations,…
-
Revenue Forecast Raise and Defense Backlog Surge Put Ondas Growth Story in Focus (ONDS)
Ondas raised its 2026 revenue outlook to at least $390 million as acquisitions, defense demand, and counter-drone contracts rapidly expanded the company’s backlog and operating platform. Key Investor Takeaways Why Ondas Stock Is in Focus Ondas reported first-quarter 2026 revenue of $50.1 million, up from $4.3 million in the same period last year. The company…
-
Drone Backlog and Defense Expansion Drive AIRO’s 2026 Growth Outlook Despite Q1 Losses
AIRO reiterated its full-year revenue growth forecast as the company expands its AI-enabled drone portfolio and builds a defense backlog exceeding $150 million. Key Investor Takeaways Why AIRO Stock Is in Focus AIRO reported first-quarter 2026 revenue of $8.9 million, down from $11.8 million in the same period last year. Gross profit declined to $2.4…
-
LiDAR Expansion Into Defense Market Keeps Innoviz Growth Narrative Intact Despite Revenue Decline (INVZ)
Innoviz reaffirmed its 2026 outlook while highlighting new defense and autonomous driving opportunities, even as first-quarter revenue fell sharply year over year. Key Investor Takeaways Why Innoviz Stock Is in Focus Innoviz reported first-quarter 2026 revenue of $7.1 million, down from $17.4 million in the same period last year. The company attributed the decline partly…
-
Cargo and Vehicle Inspection Order Adds New Government Business for OSI Systems (OSIS)
A new $15 million government task order expands OSI Systems’ security backlog and reinforces demand for its cargo and vehicle inspection technologies. Key Investor Takeaways Why OSI Systems Stock Is in Focus OSI Systems announced that its Security division received a task order worth approximately $15 million from a U.S. government customer. Under the agreement,…
-
Regenxbio Shares Rise After Positive Duchenne Trial Results
Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weaker-than-expected quarterly financial results. Earnings and Revenue Miss Expectations Regenxbio reported a first-quarter loss of $1.72 per share, wider than analyst expectations of a $1.34 loss per share.…
-
Biogen Shares Surge After Positive Mid-Stage Alzheimer’s Trial Results
Biogen (NASDAQ:BIIB) shares jumped 10% on Thursday after the company released encouraging Phase 2 data for diranersen, its experimental Alzheimer’s treatment targeting tau protein accumulation. The results came from the company’s CELIA study, which evaluated the therapy in patients with early-stage Alzheimer’s disease. Trial Shows Reductions in Tau Pathology Biogen said diranersen produced significant reductions…